HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance83% confidence

FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Domperidone.

Regulatory Analysis

Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

Supporting Context

Therapeutic area
Gastroenterology · Antiemetic
Sub-indication
Hypertension

Related signal: Domperidone Updated with New Contraindication for Phaeochromocytoma Patients

Source

View source document

Related Signal

Open signal — Domperidone Updated with New Contraindication for Phaeochromocytoma Patients
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.